Overview

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Manhattan Medical Research Practice, PLLC
Collaborator:
Endo Pharmaceuticals